Financial Ratios OncoSil Medical Limited

Equities

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 01:47:38 2025-06-20 am EDT			5-day change	1st Jan Change
1.005 ^AUD	-2.43%		+10.44%	-58.12%

May. 25	Oncosil Medical Says A$8.7M Capital Raise At Issue Price A$0.003 Per Share	RE
May. 21	Oncosil Medical Seeks Trading Halt	RE

792338.pbLfz6Fv1qtHvxOrSrFLZAErIRq6qCX4wEGwabgu1pQ.5vqRvuAh4-wiymPaM9UEXXQTFFn323yNlnDSOYEZ--TI-Oih1Am45iCISg

Published financial data: ONCOSIL MEDICAL LIMITED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: June	2020	2021	2022	2023	2024
Revenues	-	213K	232K	368K	517K
Other Revenues, Total	2.76M	1.09M	832K	1.1M	1.05M
Total Revenues	2.76M	1.3M	1.06M	1.47M	1.57M
Cost of Goods Sold, Total	-	961K	972K	1.59M	1.51M
Gross Profit	2.76M	337K	90.91K	-121K	55.63K
Selling General & Admin Expenses, Total	3.48M	7.99M	8.29M	8.36M	9.05M
Stock-Based Compensation (IS)	-	-	-	-	-
R&D Expenses	3.73M	2.89M	2.38M	2.85M	2.99M
Other Operating Expenses, Total	7.21M	10.88M	10.67M	11.21M	12.04M
Operating Income	-4.45M	-10.54M	-10.58M	-11.34M	-11.98M
Interest Expense, Total	-11.08K	-15.75K	-19.62K	-10.9K	-3.94K
Interest And Investment Income	105K	82.48K	10.13K	62.61K	66.56K
Net Interest Expenses	93.8K	66.74K	-9.49K	51.71K	62.62K
Currency Exchange Gains (Loss)	1.09K	-104K	-139K	-59.14K	7.96K
Other Non Operating Income (Expenses)	-	-	-	-	-
EBT, Excl. Unusual Items	-4.35M	-10.58M	-10.73M	-11.34M	-11.91M
Gain (Loss) On Sale Of Investments	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-
Other Unusual Items	89K	146K	-	-	-
EBT, Incl. Unusual Items	-4.26M	-10.43M	-10.73M	-11.34M	-11.91M
Earnings From Continuing Operations	-4.26M	-10.43M	-10.73M	-11.34M	-11.91M
Net Income to Company	-4.26M	-10.43M	-10.73M	-11.34M	-11.91M
Net Income - (IS)	-4.26M	-10.43M	-10.73M	-11.34M	-11.91M
Net Income to Common Incl Extra Items	-4.26M	-10.43M	-10.73M	-11.34M	-11.91M
Net Income to Common Excl. Extra Items	-4.26M	-10.43M	-10.73M	-11.34M	-11.91M
Per Share Items
Net EPS - Basic	-2.6	-5.1	-5.29	-4.02	-2.15
Basic EPS - Continuing Operations	-2.6	-5.1	-5.29	-4.02	-2.15
Basic Weighted Average Shares Outstanding	1.64M	2.05M	2.03M	2.82M	5.55M
Net EPS - Diluted	-2.6	-5.12	-5.29	-4.02	-2.16
Diluted EPS - Continuing Operations	-2.6	-5.12	-5.29	-4.02	-2.16
Diluted Weighted Average Shares Outstanding	1.64M	2.05M	2.03M	2.82M	5.55M
Normalized Basic EPS	-1.66	-3.23	-3.31	-2.51	-1.34
Normalized Diluted EPS	-1.66	-3.23	-3.31	-2.51	-1.34
Supplemental Items
EBITDA	-4.42M	-10.51M	-10.55M	-11.32M	-11.98M
EBITA	-4.45M	-10.54M	-10.58M	-11.34M	-11.98M
EBIT	-4.45M	-10.54M	-10.58M	-11.34M	-11.98M
EBITDAR	-4.29M	-10.36M	-10.49M	-11.23M	-11.85M
Normalized Net Income	-2.72M	-6.61M	-6.7M	-7.09M	-7.45M
Interest on Long-Term Debt	10.22K	14.67K	19.62K	10.9K	3.38K
Supplemental Operating Expense Items
Marketing Expenses	-	685K	370K	130K	196K
Selling and Marketing Expenses	-	685K	370K	130K	196K
General and Administrative Expenses	2.26M	2.01M	2M	3.05M	4.1M
Research And Development Expense From Footnotes	3.73M	2.89M	2.38M	2.85M	2.99M
Net Rental Expense, Total	131K	148K	57.85K	83.31K	125K
Imputed Operating Lease Interest Expense	-	62.72K	23.04K	30.59K	32.72K
Imputed Operating Lease Depreciation	-	85.23K	34.82K	52.72K	92.49K
Stock-Based Comp., SG&A Exp. (Total)	-2.39M	-141K	593K	386K	615K
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	-2.39M	-141K	593K	386K	615K

Fiscal Period: June	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	21M	12.24M	11.28M	9.39M	4.5M
Trading Asset Securities, Total	-	-	-	-	-
Total Cash And Short Term Investments	21M	12.24M	11.28M	9.39M	4.5M
Accounts Receivable, Total	2.76M	1.11M	848K	1.16M	1.36M
Other Receivables	42.27K	75.56K	59.64K	125K	73.94K
Total Receivables	2.81M	1.18M	908K	1.29M	1.44M
Prepaid Expenses	48.55K	108K	468K	439K	392K
Other Current Assets, Total	69.21K	90.53K	89.27K	117K	-
Total Current Assets	23.92M	13.62M	12.74M	11.23M	6.33M
Gross Property Plant And Equipment	-	-	-	-	525K
Accumulated Depreciation	-	-	-	-	-135K
Net Property Plant And Equipment	138K	531K	325K	239K	390K
Total Assets	24.06M	14.15M	13.07M	11.47M	6.72M
Liabilities
Accounts Payable, Total	1.36M	1.23M	931K	960K	1.12M
Accrued Expenses, Total	485K	510K	343K	164K	341K
Short-term Borrowings	26.56K	-	-	-	-
Current Portion of Leases	83.38K	163K	165K	146K	32.22K
Other Current Liabilities	208K	232K	328K	299K	447K
Total Current Liabilities	2.16M	2.13M	1.77M	1.57M	1.94M
Long-Term Leases	-	321K	139K	24.56K	38.45K
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	2.16M	2.45M	1.91M	1.59M	1.98M
Common Stock, Total	70.14M	70.4M	79.91M	86.51M	90.09M
Retained Earnings	-51.86M	-62.3M	-73.02M	-84.37M	-92.78M
Comprehensive Income and Other	3.63M	3.6M	4.28M	7.74M	7.42M
Total Common Equity	21.9M	11.7M	11.16M	9.88M	4.74M
Total Equity	21.9M	11.7M	11.16M	9.88M	4.74M
Total Liabilities And Equity	24.06M	14.15M	13.07M	11.47M	6.72M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2.07M	1.99M	2.48M	4.94M	8.33M
ECS Total Common Shares Outstanding	2.07M	1.99M	2.48M	4.94M	8.33M
Book Value / Share	10.57	5.87	4.5	2	0.57
Tangible Book Value	21.9M	11.7M	11.16M	9.88M	4.74M
Tangible Book Value Per Share	10.57	5.87	4.5	2	0.57
Total Debt	110K	484K	304K	171K	70.67K
Net Debt	-20.89M	-11.76M	-10.98M	-9.22M	-4.43M
Debt Equivalent Oper. Leases	1.05M	1.18M	463K	666K	1M
Account Code - Inventory Valuation	3	3	-	-	3
Machinery, Total	-	-	-	-	97.41K

Fiscal Period: June	2020	2021	2022	2023	2024
Net Income	-4.26M	-10.43M	-10.73M	-11.34M	-11.91M
Depreciation & Amortization - CF	149K	185K	192K	176K	44K
Depreciation & Amortization, Total	149K	185K	192K	176K	44K
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-	-	-	-	-
Stock-Based Compensation (CF)	-2.39M	-141K	593K	386K	615K
Other Operating Activities, Total	-1.13K	109K	87.37K	-2.56K	-72.21K
Change In Accounts Receivable	-	-28.69K	274K	-378K	45.82K
Change In Accounts Payable	1.01M	-49.32K	-74.31K	-78.54K	471K
Change in Other Net Operating Assets	1.04M	1.54M	-455K	-75.17K	-14.82K
Cash from Operations	-4.46M	-8.82M	-10.11M	-11.32M	-10.82M
Capital Expenditure	-20.72K	-54K	-5.83K	-57.82K	-197K
Investment in Marketable and Equity Securities, Total	-	-	-	-	-
Cash from Investing	-20.72K	-54K	-5.83K	-57.82K	-197K
Short Term Debt Issued, Total	26.56K	-	-	-	-
Total Debt Issued	26.56K	-	-	-	-
Short Term Debt Repaid, Total	-	-26.56K	-	-	-
Long-Term Debt Repaid, Total	-121K	-122K	-160K	-187K	-60.4K
Total Debt Repaid	-121K	-149K	-160K	-187K	-60.4K
Issuance of Common Stock	19.04M	-	9.32M	6.6M	3.59M
Other Financing Activities, Total	-1.16M	260K	-	3.08M	2.6M
Cash from Financing	17.79M	111K	9.16M	9.49M	6.13M
Net Change in Cash	13.31M	-8.76M	-960K	-1.89M	-4.89M
Supplemental Items
Cash Interest Paid	11.08K	15.75K	19.62K	10.9K	3.94K
Cash Income Tax Paid (Refund)	-3.72M	-2.76M	-832K	-821K	-1.1M
Levered Free Cash Flow	-3M	-5.14M	-6.3M	-7.14M	-6.53M
Unlevered Free Cash Flow	-2.99M	-5.13M	-6.28M	-7.14M	-6.53M
Change In Net Working Capital	-2.05M	-1.46M	452K	556K	-502K
Net Debt Issued / Repaid	-94.53K	-149K	-160K	-187K	-60.4K

Fiscal Period: June	2020	2021	2022	2023	2024
Profitability
Return on Assets	-15.55	-34.49	-48.58	-57.73	-82.34
Return on Total Capital	-17	-38.54	-55.91	-65.85	-100.82
Return On Equity %	-26.17	-62.11	-93.85	-107.81	-163.01
Return on Common Equity	-26.17	-62.11	-93.85	-107.81	-163.01
Margin Analysis
Gross Profit Margin %	100	25.98	8.55	-8.27	3.55
SG&A Margin	126.03	615.52	779.79	569.92	578.14
EBITDA Margin %	-159.89	-809.41	-991.98	-771.1	-765.06
EBITA Margin %	-160.86	-811.96	-994.72	-772.48	-765.58
EBIT Margin %	-160.86	-811.96	-994.72	-772.48	-765.58
Income From Continuing Operations Margin %	-154.2	-803.61	-1.01K	-772.98	-761.07
Net Income Margin %	-154.2	-803.61	-1.01K	-772.98	-761.07
Net Avail. For Common Margin %	-154.2	-803.61	-1.01K	-772.98	-761.07
Normalized Net Income Margin	-98.39	-509.29	-630.46	-483.11	-475.67
Levered Free Cash Flow Margin	-108.52	-396.19	-592.09	-486.82	-417.03
Unlevered Free Cash Flow Margin	-108.27	-395.43	-590.93	-486.36	-416.87
Asset Turnover
Asset Turnover	0.15	0.07	0.08	0.12	0.17
Fixed Assets Turnover	27.52	3.88	2.49	5.2	4.98
Receivables Turnover (Average Receivables)	-	0.11	0.24	0.37	0.41
Short Term Liquidity
Current Ratio	11.08	6.39	7.21	7.16	3.26
Quick Ratio	11.03	6.29	6.89	6.81	3.05
Operating Cash Flow to Current Liabilities	-2.06	-4.13	-5.72	-7.21	-5.57
Days Sales Outstanding (Average Receivables)	-	3.31K	1.54K	997.23	893.57
Average Days Payable Outstanding	-	490.43	404.98	217.24	252.56
Long Term Solvency
Total Debt/Equity	0.5	4.14	2.73	1.73	1.49
Total Debt / Total Capital	0.5	3.98	2.65	1.7	1.47
LT Debt/Equity	-	2.75	1.24	0.25	0.81
Long-Term Debt / Total Capital	-	2.64	1.21	0.24	0.8
Total Liabilities / Total Assets	8.97	17.34	14.59	13.89	29.5
EBIT / Interest Expense	-401.06	-669.45	-539.02	-1.04K	-3.04K
EBITDA / Interest Expense	-387.6	-657.72	-529.25	-1.02K	-3.03K
(EBITDA - Capex) / Interest Expense	-389.46	-661.15	-529.54	-1.03K	-3.08K
Total Debt / EBITDA	-0.03	-0.05	-0.03	-0.02	-0.01
Net Debt / EBITDA	4.86	1.14	1.06	0.83	0.37
Total Debt / (EBITDA - Capex)	-0.03	-0.05	-0.03	-0.02	-0.01
Net Debt / (EBITDA - Capex)	4.84	1.13	1.06	0.82	0.37
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-23.78	-53.02	-18.1	38	6.68
Gross Profit, 1 Yr. Growth %	-23.78	-87.8	-73.05	-233.48	-145.84
EBITDA, 1 Yr. Growth %	-49.48	138.57	0.38	7.27	5.84
EBITA, 1 Yr. Growth %	-49.4	137.89	0.34	7.16	5.72
EBIT, 1 Yr. Growth %	-49.4	137.89	0.34	7.16	5.72
Earnings From Cont. Operations, 1 Yr. Growth %	-50.25	144.81	2.81	5.74	5.03
Net Income, 1 Yr. Growth %	-50.25	144.81	2.81	5.74	5.03
Normalized Net Income, 1 Yr. Growth %	-49.21	143.16	1.39	5.74	5.03
Diluted EPS Before Extra, 1 Yr. Growth %	-52.31	96.92	3.36	-24.1	-46.22
Accounts Receivable, 1 Yr. Growth %	-26.91	-59.98	-23.31	36.89	17.28
Net Property, Plant and Equip., 1 Yr. Growth %	121.52	283.59	-38.78	-26.37	62.89
Total Assets, 1 Yr. Growth %	106.2	-41.19	-7.64	-12.21	-41.45
Tangible Book Value, 1 Yr. Growth %	105.16	-46.59	-4.56	-11.49	-52.06
Common Equity, 1 Yr. Growth %	105.16	-46.59	-4.56	-11.49	-52.06
Cash From Operations, 1 Yr. Growth %	-40.59	97.83	14.69	11.92	-4.34
Capital Expenditures, 1 Yr. Growth %	39.74	160.61	-89.2	891.41	240.82
Levered Free Cash Flow, 1 Yr. Growth %	-31.75	71.5	22.4	13.46	-8.62
Unlevered Free Cash Flow, 1 Yr. Growth %	-31.9	72.08	22.4	13.57	-8.56
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-21.17	-40.16	-37.97	6.31	21.33
Gross Profit, 2 Yr. CAGR %	-21.17	-69.5	-81.86	-40.02	-21.77
EBITDA, 2 Yr. CAGR %	-28.32	9.61	54.75	3.77	6.55
EBITA, 2 Yr. CAGR %	-28.27	9.54	54.5	3.7	6.44
EBIT, 2 Yr. CAGR %	-28.27	9.54	54.5	3.7	6.44
Earnings From Cont. Operations, 2 Yr. CAGR %	-29.35	10.36	58.65	4.27	5.39
Net Income, 2 Yr. CAGR %	-29.35	10.36	58.65	4.27	5.39
Normalized Net Income, 2 Yr. CAGR %	-28.62	11.13	57.02	3.55	5.39
Diluted EPS Before Extra, 2 Yr. CAGR %	-37.42	-3.09	42.67	-11.43	-36.11
Accounts Receivable, 2 Yr. CAGR %	-21.12	-45.92	-44.6	2.46	26.71
Net Property, Plant and Equip., 2 Yr. CAGR %	26.66	191.5	53.24	-32.86	9.52
Total Assets, 2 Yr. CAGR %	10.01	10.12	-26.3	-9.95	-28.3
Tangible Book Value, 2 Yr. CAGR %	9.83	4.67	-28.61	-8.09	-34.86
Common Equity, 2 Yr. CAGR %	9.83	4.67	-28.61	-8.09	-34.86
Cash From Operations, 2 Yr. CAGR %	-27.15	8.41	50.63	13.3	3.47
Capital Expenditures, 2 Yr. CAGR %	39.19	90.83	-46.95	3.48	481.29
Levered Free Cash Flow, 2 Yr. CAGR %	-24.29	8.19	44.89	17.85	1.83
Unlevered Free Cash Flow, 2 Yr. CAGR %	-24.38	8.09	45.13	17.9	1.91
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-7.7	-33.66	-33.56	-19.03	6.43
Gross Profit, 3 Yr. CAGR %	-7.7	-57.67	-70.73	-64.72	-45.16
EBITDA, 3 Yr. CAGR %	-15.27	6.9	6.44	36.96	4.45
EBITA, 3 Yr. CAGR %	-15.22	6.85	6.38	36.76	4.37
EBIT, 3 Yr. CAGR %	-15.22	6.85	6.38	36.76	4.37
Earnings From Cont. Operations, 3 Yr. CAGR %	-15.31	6.91	7.78	38.58	4.52
Net Income, 3 Yr. CAGR %	-15.31	6.91	7.78	38.58	4.52
Normalized Net Income, 3 Yr. CAGR %	-15.01	7.4	7.78	37.63	4.04
Diluted EPS Before Extra, 3 Yr. CAGR %	-24.17	-8.3	-0.99	15.6	-25
Accounts Receivable, 3 Yr. CAGR %	-7.1	-37.09	-39.24	-25.1	7.18
Net Property, Plant and Equip., 3 Yr. CAGR %	6.22	83.25	73.27	20.03	-9.78
Total Assets, 3 Yr. CAGR %	26.79	-10.72	3.85	-21.87	-21.99
Tangible Book Value, 3 Yr. CAGR %	29.29	-13.63	1.5	-23.3	-26.02
Common Equity, 3 Yr. CAGR %	29.29	-13.63	1.5	-23.3	-26.02
Cash From Operations, 3 Yr. CAGR %	-9.99	1.63	10.46	36.43	7.08
Capital Expenditures, 3 Yr. CAGR %	-26.83	71.55	-26.73	40.78	53.96
Levered Free Cash Flow, 3 Yr. CAGR %	-5.31	-0.57	12.74	33.55	8.27
Unlevered Free Cash Flow, 3 Yr. CAGR %	-5.38	-0.63	12.66	33.74	8.32
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	0.05	-19.49	-21.27	-19.89	-15.46
Gross Profit, 5 Yr. CAGR %	0.05	-38.51	-51.85	-51.34	-56.63
EBITDA, 5 Yr. CAGR %	8.83	15.95	7.74	5.64	6.49
EBITA, 5 Yr. CAGR %	8.91	15.93	7.71	5.58	6.41
EBIT, 5 Yr. CAGR %	8.91	15.93	7.71	5.58	6.41
Earnings From Cont. Operations, 5 Yr. CAGR %	8.16	16.95	8.86	5.84	6.82
Net Income, 5 Yr. CAGR %	8.16	16.95	8.86	5.84	6.82
Normalized Net Income, 5 Yr. CAGR %	10.4	17.46	8.64	5.84	6.82
Diluted EPS Before Extra, 5 Yr. CAGR %	-4.31	0.8	-2.36	-9.56	-16.9
Accounts Receivable, 5 Yr. CAGR %	-	-13.6	-24.45	-23.53	-18.47
Net Property, Plant and Equip., 5 Yr. CAGR %	20.23	42.07	22.99	22.64	44.22
Total Assets, 5 Yr. CAGR %	26.57	-2.3	2.06	-10.41	-10.45
Tangible Book Value, 5 Yr. CAGR %	25.76	-4.61	1.95	-11.46	-15
Common Equity, 5 Yr. CAGR %	25.76	-4.61	1.95	-11.46	-15
Cash From Operations, 5 Yr. CAGR %	91.92	14.03	10.6	6.15	7.61
Capital Expenditures, 5 Yr. CAGR %	-14.45	-1.41	-35.66	40.14	67.77
Levered Free Cash Flow, 5 Yr. CAGR %	107.27	9.49	12.25	6.42	8.24
Unlevered Free Cash Flow, 5 Yr. CAGR %	107.17	9.45	12.21	6.4	8.23